Helen Torley joins Onyx Pharmaceuticals
Takes the position of executive vp and chief commercial officer
Torley reports to Anthony Coles, president and chief executive officer, and take responsibility for all commercial activities related to Nexavar and the potential launch of carfilzomib, the development of the company's European commercial organisation, and initiatives to grow business and capabilities in the US and Europe.
Before joining Onyx, Torley spent nine years at Amgen where she most recently served as vice president and general manager of the Bone Health Business Unit, after leading the company's Nephrology Business Unit for five years.
From 1997 to 2002, she held various senior management positions at Bristol Myers Squibb.
Torley began her industry career at Sandoz/Novartis, where she ultimately served as Vice President of Medical Affairs, overseeing phase IIIb and IV clinical studies across all therapeutic areas, including oncology.
You may also like
Pharmaceutical
Enanta Pharma files patent infringement suit against Pfizer in the Unified Patent Court of the EU
The company is seeking a determination of liability for use and infringement of European Patent No. EP 4 051 265 (the 265 Patent) in the manufacture, use and sale of Pfizer’s COVID-19 antiviral, Paxlovid (nirmatrelvir tablets; ritonavir tablets)
Regulatory
The foundations of pharmaceutical compliance for beginners
Whether you’re stepping into the pharmaceutical industry for the first time or pivoting into a compliance or quality assurance role after years of experience, mastering the fundamentals of quality and regulatory compliance is vital to your success—and to the success of your organisation
Manufacturing
WLS introduces PR-12 and PR-24 plunger rod insertion and labelling systems
By improving reliability and streamlining production, the PR-12 and PR-24 help pharmaceutical manufacturers and contract packers protect product quality and reduce waste while maximising operational efficiencies
Pharmaceutical
Azelis strengthens its footprint in Italy with the acquisition of Azienda Chimica e Farmaceutica (‘ACEF’)
Azelis is pleased to announce that it has acquired 100% of the shares of Azienda Chimica e Farmaceutica (‘ACEF’), a distributor of speciality raw materials and ingredients for the cosmetic, nutraceutical, galenic and pharma industries in Italy